BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49:S156-S165. [PMID: 19399803 DOI: 10.1002/hep.22945] [Cited by in Crossref: 375] [Cited by in F6Publishing: 314] [Article Influence: 31.3] [Reference Citation Analysis]
Number Citing Articles
1 Visram A, Feld JJ. Defining and grading HBV reactivation: Defining and Grading HBV Reactivation. Clinical Liver Disease. 2015;5:35-38. [PMID: 31040945 DOI: 10.1002/cld.426] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
2 Ahn SS, Jung SM, Song JJ, Park YB, Park JY, Lee SW. Safety of Tocilizumab in Rheumatoid Arthritis Patients with Resolved Hepatitis B Virus Infection: Data from Real-World Experience. Yonsei Med J 2018;59:452-6. [PMID: 29611409 DOI: 10.3349/ymj.2018.59.3.452] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
3 Restellini S, Chazouillères O, Frossard JL. Hepatic manifestations of inflammatory bowel diseases. Liver Int 2017;37:475-89. [PMID: 27712010 DOI: 10.1111/liv.13265] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
4 Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open. 2016;1:e000042. [PMID: 27843598 DOI: 10.1136/esmoopen-2016-000042] [Cited by in Crossref: 108] [Cited by in F6Publishing: 82] [Article Influence: 21.6] [Reference Citation Analysis]
5 Dao DY, Hynan LS, Yuan HJ, Sanders C, Balko J, Attar N, Lok AS, Word RA, Lee WM;  Acute Liver Failure Study Group. Two distinct subtypes of hepatitis B virus-related acute liver failure are separable by quantitative serum immunoglobulin M anti-hepatitis B core antibody and hepatitis B virus DNA levels. Hepatology. 2012;55:676-684. [PMID: 21987355 DOI: 10.1002/hep.24732] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
6 Hwang JP, Fisch MJ, Zhang H, Kallen MA, Routbort MJ, Lal LS, Vierling JM, Suarez-Almazor ME. Low rates of hepatitis B virus screening at the onset of chemotherapy. J Oncol Pract. 2012;8:e32-e39. [PMID: 23180996 DOI: 10.1200/jop.2011.000450] [Cited by in Crossref: 61] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
7 Hollinger FB, Sood G. Occult hepatitis B virus infection: a covert operation. J Viral Hepat. 2010;17:1-15. [PMID: 20002296 DOI: 10.1111/j.1365-2893.2009.01245.x] [Cited by in Crossref: 110] [Cited by in F6Publishing: 107] [Article Influence: 9.2] [Reference Citation Analysis]
8 Hagiwara S, Sakurai T, Nishina S, Tanaka K, Ikeda M, Ueshima K, Minami Y, Inoue T, Yada N, Kitai S, Takita M, Nagai T, Hayaishi S, Arizumi T, Park AM, Munakata H, Nishida N, Kudo M. Characteristic pattern of reactivation of hepatitis B virus during chemotherapy for solid cancers. Dig Dis 2012;30:541-6. [PMID: 23258092 DOI: 10.1159/000343056] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
9 Bath RM, Doering BE, Nailor MD, Goodlet KJ. Pharmacotherapy-Induced Hepatitis B Reactivation Among Patients With Prior Functional Cure: A Systematic Review. Ann Pharmacother 2019;53:294-310. [PMID: 30203666 DOI: 10.1177/1060028018800501] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
10 Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex 2021:S0375-0906(21)00061-6. [PMID: 34384668 DOI: 10.1016/j.rgmx.2021.04.002] [Reference Citation Analysis]
11 Li HR, Huang JJ, Guo HQ, Zhang X, Xie Y, Zhu HL, Zhai LZ, Pu XX, Huang Y, Guo CC. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat. 2011;18:877-883. [PMID: 21054683 DOI: 10.1111/j.1365-2893.2010.01386.x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 6.4] [Reference Citation Analysis]
12 Zachou K, Dalekos GN. Hepatitis B re-activation with rituximab therapy: treat the patient not the disease. Liver Int. 2011;31:277-279. [PMID: 21281426 DOI: 10.1111/j.1478-3231.2011.02452.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
13 Meng C, Belino C, Pereira L, Pinho A, Sampaio S, Tavares I, Bustorff M, Sarmento A, Pestana M. Reactivation of Hepatitis B virus in kidney transplant recipients with previous clinically resolved infection: A single-center experience. Nefrologia (Engl Ed) 2018;38:545-50. [PMID: 29709320 DOI: 10.1016/j.nefro.2018.02.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
14 Mawatari S, Uto H, Moriuchi A, Tabu K, Muromachi K, Tabu E, Oda K, Imanaka D, Oshige A, Nakazawa J, Kumagai K, Tamai T, Okamoto H, Tsubouchi H, Ido A. Horizontal transmission of de novo hepatitis B between spouses: A case report. Hepatol Res 2015;45:933-8. [PMID: 25211282 DOI: 10.1111/hepr.12422] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
15 Sulkowski MS, Chuang WL, Kao JH, Yang JC, Gao B, Brainard DM, Han KH, Gane E. No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection. Clin Infect Dis. 2016;63:1202-1204. [PMID: 27486112 DOI: 10.1093/cid/ciw507] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
16 Gujar SA, Mulrooney-Cousins PM, Michalak TI. Repeated exposure to trace amounts of woodchuck hepadnavirus induces molecularly evident infection and virus-specific T cell response in the absence of serological infection markers and hepatitis. J Virol 2013;87:1035-48. [PMID: 23135718 DOI: 10.1128/JVI.01363-12] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
17 Piermatteo L, Scutari R, Chirichiello R, Alkhatib M, Malagnino V, Bertoli A, Iapadre N, Ciotti M, Sarmati L, Andreoni M, Ceccherini-Silberstein F, Salpini R, Svicher V. Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment. Methods 2021:S1046-2023(21)00137-7. [PMID: 34000391 DOI: 10.1016/j.ymeth.2021.05.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Bossé D, Ng T, Ahmad C, Alfakeeh A, Alruzug I, Biagi J, Brierley J, Chaudhury P, Cleary S, Colwell B, Cripps C, Dawson LA, Dorreen M, Ferland E, Galiatsatos P, Girard S, Gray S, Halwani F, Kopek N, Mahmud A, Martel G, Robillard L, Samson B, Seal M, Siddiqui J, Sideris L, Snow S, Thirwell M, Vickers M, Goodwin R, Goel R, Hsu T, Tsvetkova E, Ward B, Asmis T. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016. Curr Oncol 2016;23:e605-14. [PMID: 28050151 DOI: 10.3747/co.23.3394] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
19 Zou CJ, Zhu LJ, Li YH, Mo YQ, Zheng DH, Ma JD, Ou-Yang X, Pessler F, Dai L. The association between hepatitis B virus infection and disease activity, synovitis, or joint destruction in rheumatoid arthritis. Clin Rheumatol. 2013;32:787-795. [PMID: 23340833 DOI: 10.1007/s10067-013-2170-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
20 Larrubia JR. Occult hepatitis B virus infection: a complex entity with relevant clinical implications. World J Gastroenterol. 2011;17:1529-1530. [PMID: 21472115 DOI: 10.3748/wjg.v17.i12] [Reference Citation Analysis]
21 Kostyushev D, Brezgin S, Kostyusheva A, Zarifyan D, Goptar I, Chulanov V. Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus. Cell Mol Life Sci. 2019;76:1779-1794. [PMID: 30673820 DOI: 10.1007/s00018-019-03021-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
22 Li C, Li ZC, Ma L, Li LQ, Zhong JH, Xiang BD, Gong WF. Perioperative antiviral therapy improves the prognosis of HBV DNA-negative patients with HBV-related hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2020;14:749-56. [PMID: 32552297 DOI: 10.1080/17474124.2020.1784727] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Tugizova M, Vlahovic L, Tomczak A, Wetzel NS, Han MH. New Therapeutic Landscape in Neuromyelitis Optica. Curr Treat Options Neurol 2021;23:13. [PMID: 33814893 DOI: 10.1007/s11940-021-00667-3] [Reference Citation Analysis]
24 Urbani S, Fagnoni F, Missale G, Franchini M. The role of anti-core antibody response in the detection of occult hepatitis B virus infection. Clin Chem Lab Med. 2010;48:23-29. [PMID: 19919328 DOI: 10.1515/cclm.2010.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
25 Lok AS, Zoulim F, Dusheiko G, Chan HLY, Buti M, Ghany MG, Gaggar A, Yang JC, Wu G, Flaherty JF, Subramanian GM, Locarnini S, Marcellin P. Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B. Hepatol Commun 2020;4:8-20. [PMID: 31909352 DOI: 10.1002/hep4.1436] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
26 Franz C, Perez Rde M, Zalis MG, Zalona AC, Rocha PT, Gonçalves RT, Nabuco LC, Villela-Nogueira CA. Prevalence of occult hepatitis B virus infection in kidney transplant recipients. Mem Inst Oswaldo Cruz. 2013;108:657-660. [PMID: 23903984 DOI: 10.1590/0074-0276108052013019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
27 Teplinsky E, Cheung D, Weisberg I, Jacobs RE, Wolff M, Park J, Friedman K, Muggia F, Jhaveri K. Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature. Breast Cancer Res Treat. 2013;141:167-172. [PMID: 24002736 DOI: 10.1007/s10549-013-2681-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
28 Puri P. Acute exacerbation of chronic hepatitis B: the dilemma of differentiation from acute viral hepatitis B. J Clin Exp Hepatol 2013;3:301-12. [PMID: 25755518 DOI: 10.1016/j.jceh.2013.08.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
29 Lenci I, Tisone G, Di Paolo D, Marcuccilli F, Tariciotti L, Ciotti M, Svicher V, Perno CF, Angelico M. Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. J Hepatol. 2011;55:587-593. [PMID: 21251938 DOI: 10.1016/j.jhep.2010.12.036] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 6.1] [Reference Citation Analysis]
30 Querido S, Weigert A, Adragão T, Rodrigues L, Jorge C, Bruges M, Machado D. Risk of hepatitis B reactivation in hepatitis B surface antigen seronegative and core antibody seropositive kidney transplant recipients. Transpl Infect Dis 2019;21:e13009. [PMID: 30295412 DOI: 10.1111/tid.13009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
31 Cedeño-moreno D, Vargas-lombardo M, Salas-zárate MP, Paredes-valverde MA, Valencia-garcía R. Analysis of Mobile Applications for Self-healthcare of Panamanian Patients with Hepatitis. In: Valencia-garcía R, Lagos-ortiz K, Alcaraz-mármol G, Del Cioppo J, Vera-lucio N, Bucaram-leverone M, editors. Technologies and Innovation. Cham: Springer International Publishing; 2017. pp. 17-28. [DOI: 10.1007/978-3-319-67283-0_2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Massoumi H, Martin P, Tan H. Management of chronic hepatitis B: . European Journal of Gastroenterology & Hepatology 2011;23:642-50. [DOI: 10.1097/meg.0b013e3283474add] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
33 Visram A, Chan KK, McGee P, Boro J, Hicks LK, Feld JJ. Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening. PLoS One. 2015;10:e0120749. [PMID: 25875198 DOI: 10.1371/journal.pone.0120749] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
34 Zobeiri M. Occult hepatitis B: clinical viewpoint and management. Hepat Res Treat. 2013;2013:259148. [PMID: 23533738 DOI: 10.1155/2013/259148] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
35 Tamori A, Hino M, Kawamura E, Fujii H, Uchida-Kobayashi S, Morikawa H, Nakamae H, Enomoto M, Murakami Y, Kawada N. Prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy. J Gastroenterol Hepatol. 2014;29:1715-1721. [PMID: 24730465 DOI: 10.1111/jgh.12604] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
36 Droz N, Gilardin L, Cacoub P, Berenbaum F, Wendling D, Godeau B, Piette AM, Dernis E, Ebbo M, Fautrel B. Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases. Arthritis Care Res (Hoboken). 2013;65:1504-1514. [PMID: 23436730 DOI: 10.1002/acr.21990] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
37 Motaparthi K, Stanisic V, Van Voorhees AS, Lebwohl MG, Hsu S. From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. J Am Acad Dermatol. 2014;70:178-186. [PMID: 24220724 DOI: 10.1016/j.jaad.2013.08.049] [Cited by in Crossref: 42] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
38 Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer.Nat Rev Clin Oncol. 2012;9:156-166. [PMID: 22271089 DOI: 10.1038/nrclinonc.2012.1] [Cited by in Crossref: 107] [Cited by in F6Publishing: 86] [Article Influence: 11.9] [Reference Citation Analysis]
39 Jüngst C, Berg T, Cheng J, Green RM, Jia J, Mason AL, Lammert F. Intrahepatic cholestasis in common chronic liver diseases. Eur J Clin Invest. 2013;43:1069-1083. [PMID: 23927644 DOI: 10.1111/eci.12128] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
40 Chung YL. Defective DNA damage response and repair in liver cells expressing hepatitis B virus surface antigen. FASEB J. 2013;27:2316-2327. [PMID: 23444429 DOI: 10.1096/fj.12-226639] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
41 Jaillais A, Herber-Mayne A, D'Alteroche L, Landau A, Merrouche Y, Vignot S. [HBV infection: Screening and treatment for oncology patients]. Bull Cancer 2018;105:162-70. [PMID: 29066086 DOI: 10.1016/j.bulcan.2017.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Jafri SR, Lok AS. Antiviral Therapy for Chronic Hepatitis B. Clinics in Liver Disease 2010;14:425-38. [DOI: 10.1016/j.cld.2010.05.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
43 Parker S, Gil E, Hewitt P, Ward K, Reyal Y, Wilson S, Manson J. Case report: passive transfer of hepatitis B antibodies from intravenous immunoglobulin. BMC Infect Dis 2014;14:99. [PMID: 24559411 DOI: 10.1186/1471-2334-14-99] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
44 Invernizzi F, Viganò M, Grossi G, Lampertico P. The prognosis and management of inactive HBV carriers. Liver Int. 2016;36 Suppl 1:100-104. [PMID: 26725905 DOI: 10.1111/liv.13006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
45 Apata IW, Nguyen DB, Khudyakov Y, Mixson-Hayden T, Rosenberg J, Zahn M, Greenko J, Clement E, Portney AE, Kulkarni PA, Comer M, Adams E, Kamili S, Patel PR, Moorman AC. Hepatitis B Virus Mutant Infections in Hemodialysis Patients: A Case Series. Kidney Med 2019;1:347-53. [PMID: 32734215 DOI: 10.1016/j.xkme.2019.07.011] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Holmes JA, Yu ML, Chung RT. Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals. Expert Opin Drug Saf. 2017;16:651-672. [PMID: 28471314 DOI: 10.1080/14740338.2017.1325869] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
47 Shen Z, Gao Z, Gu C, Wu J, Wang J, Zhang J, Xie Y, Liu J. Prior transient exposure to interleukin-21 delivered by recombinant adeno-associated virus vector protects mice from hepatitis B virus persistence. Antiviral Res 2021;190:105076. [PMID: 33865876 DOI: 10.1016/j.antiviral.2021.105076] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Ogawa E, Wei MT, Nguyen MH. Hepatitis B Virus Reactivation Potentiated by Biologics. Infect Dis Clin North Am 2020;34:341-58. [PMID: 32334985 DOI: 10.1016/j.idc.2020.02.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
49 Kamitsukasa H, Iri M, Tanaka A, Nagashima S, Takahashi M, Nishizawa T, Okamoto H. Spontaneous reactivation of hepatitis B virus (HBV) infection in patients with resolved or occult HBV infection. J Med Virol 2015;87:589-600. [PMID: 25612181 DOI: 10.1002/jmv.24115] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
50 Kwak YE, Stein SM, Lim JK. Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy in a Major US Hospital Network. Dig Dis Sci 2018;63:61-71. [PMID: 29177849 DOI: 10.1007/s10620-017-4850-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
51 Chen YH, de Carvalho HM, Kalyoncu U, Llamado LJQ, Solano G, Pedersen R, Lukina G, Lichauco JJ, Vasilescu RS. Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice. Biologics 2018;12:1-9. [PMID: 29391775 DOI: 10.2147/BTT.S148606] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Papamichalis P, Alexiou A, Boulbou M, Dalekos GN, Rigopoulou EI. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy? Clin Res Hepatol Gastroenterol. 2012;36:84-93. [PMID: 21920838 DOI: 10.1016/j.clinre.2011.07.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
53 Hwang JP, Barbo AG, Perrillo RP. Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases. J Viral Hepat. 2015;22:346-352. [PMID: 25220947 DOI: 10.1111/jvh.12305] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
54 Shamliyan TA, Johnson JR, MacDonald R, Shaukat A, Yuan JM, Kane RL, Wilt TJ. Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection. J Gen Intern Med 2011;26:326-39. [PMID: 21203860 DOI: 10.1007/s11606-010-1569-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
55 Gish RG, Given BD, Lai CL, Locarnini SA, Lau JY, Lewis DL, Schluep T. Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities. Antiviral Res 2015;121:47-58. [PMID: 26092643 DOI: 10.1016/j.antiviral.2015.06.008] [Cited by in Crossref: 151] [Cited by in F6Publishing: 130] [Article Influence: 25.2] [Reference Citation Analysis]
56 Ming-Xu H, Chen M, Cai Y, Yan-Jia H. Clinical outcomes of low-dose leflunomide for rheumatoid arthritis complicated with Hepatitis B virus carriage and safety observation. Pak J Med Sci 2015;31:320-4. [PMID: 26101483 DOI: 10.12669/pjms.312.6673] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
57 Vassilopoulos D, Calabrese LH. Viral hepatitis: review of arthritic complications and therapy for arthritis in the presence of active HBV/HCV. Curr Rheumatol Rep. 2013;15:319. [PMID: 23436024 DOI: 10.1007/s11926-013-0319-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
58 Magalhães RK, Ferreira D, Salgado M, Pedroto I. Hepatitis B virus reactivation after chemotherapy in an HIV-positive patient. J Clin Gastroenterol 2013;47:565-6. [PMID: 23442838 DOI: 10.1097/MCG.0b013e318282971e] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
59 Tohme RA, Bulkow L, Homan CE, Negus S, McMahon BJ. Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B-Alaska, 2001-2010. J Clin Virol. 2013;58:396-400. [PMID: 24001884 DOI: 10.1016/j.jcv.2013.08.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
60 Lombardi A, Mondelli MU. Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects. Aliment Pharmacol Ther 2019;50:872-84. [PMID: 31378985 DOI: 10.1111/apt.15449] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
61 Pisaturo M, Onorato L, Russo A, Coppola N. Prevalence of occult HBV infection in Western countries. J Med Virol 2020. [PMID: 32275083 DOI: 10.1002/jmv.25867] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Ikeda M. Reactivation of hepatitis B virus in patients receiving chemotherapy. Jpn J Clin Oncol. 2013;43:8-16. [PMID: 23183929 DOI: 10.1093/jjco/hys191] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
63 Chen PH, Limketkai BN, Trilianos P, Pirtini-Cetingul M, Woreta TA, Kim B, Gulsen MT, Segev DL, Cameron AM, Gurakar A. Effect of prior hepatitis B virus exposure on long-term risk of liver-related events after liver transplantation. Clin Transplant 2016;30:579-88. [PMID: 26913379 DOI: 10.1111/ctr.12723] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
64 Shlomai A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol. 2014;26:78-88. [PMID: 24457013 DOI: 10.1016/j.semcancer.2014.01.004] [Cited by in Crossref: 91] [Cited by in F6Publishing: 86] [Article Influence: 13.0] [Reference Citation Analysis]
65 Kanaan N, Kabamba B, Maréchal C, Pirson Y, Beguin C, Goffin E, Hassoun Z. Significant rate of hepatitis B reactivation following kidney transplantation in patients with resolved infection. Journal of Clinical Virology 2012;55:233-8. [DOI: 10.1016/j.jcv.2012.07.015] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
66 Means S, Ali MA, Ho H, Heffernan J. Mathematical Modeling for Hepatitis B Virus: Would Spatial Effects Play a Role and How to Model It? Front Physiol 2020;11:146. [PMID: 32158403 DOI: 10.3389/fphys.2020.00146] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Matsuzaki T, Eguchi K, Nagao N, Tsuji S, Aramaki T, Terada K, Iwatsu S, Tokimura I, Kamo Y, Oda H, Kinoshita N, Miyaaki H, Taura N, Ichikawa T, Kawakami A, Nakao K, Ueki Y. Hepatitis B virus reactivation in patients with rheumatoid arthritis: A single-center study. Mod Rheumatol 2018;28:808-13. [PMID: 29256314 DOI: 10.1080/14397595.2017.1419842] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
68 Doi A, Sakamori R, Tahata Y, Urabe A, Morishita N, Yamada R, Furuta K, Kodama T, Hikita H, Yakushijin T. Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all-oral direct-acting antivirals: Analysis of a Japanese prospective cohort. Hepatol Res. 2017;47:1438-1444. [PMID: 28585404 DOI: 10.1111/hepr.12919] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
69 Wu YT, Li X, Liu ZL, Xu Z, Dai W, Zhang K, Wu JS, Arshad B, Wu KN, Kong LQ. Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysis. PLoS One 2017;12:e0179680. [PMID: 28640902 DOI: 10.1371/journal.pone.0179680] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
70 Vyas AK, Jindal A, Hissar S, Ramakrishna G, Trehanpati N. Immune balance in Hepatitis B Infection: Present and Future Therapies. Scand J Immunol 2017;86:4-14. [PMID: 28387980 DOI: 10.1111/sji.12553] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
71 Hyzny EJ, Chan EG, Morrell M, Harano T, Sanchez PG. A review of liver dysfunction in the lung transplant patient. Clin Transplant 2021;:e14344. [PMID: 33960530 DOI: 10.1111/ctr.14344] [Reference Citation Analysis]
72 Park SH, Rehermann B. Immune responses to HCV and other hepatitis viruses. Immunity 2014;40:13-24. [PMID: 24439265 DOI: 10.1016/j.immuni.2013.12.010] [Cited by in Crossref: 180] [Cited by in F6Publishing: 164] [Article Influence: 25.7] [Reference Citation Analysis]
73 Méndez-Navarro J, Corey KE, Zheng H, Barlow LL, Jang JY, Lin W, Zhao H, Shao RX, McAfee SL, Chung RT. Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int 2011;31:330-9. [PMID: 20738779 DOI: 10.1111/j.1478-3231.2010.02332.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
74 Emori CT, Perez RM, Matos CA, Uehara SN, Pereira Pda S, Feldner AC, Carvalho-Filho RJ, Silva IS, Silva AE, Ferraz ML. Acute exacerbation of chronic hepatitis B virus infection in renal transplant patients. Braz J Infect Dis 2014;18:625-30. [PMID: 25179509 DOI: 10.1016/j.bjid.2014.06.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
75 Aoki J, Kowazaki Y, Ohtsuki T, Okamoto R, Ohashi K, Hayashi S, Sakamaki H, Kohara M, Kimura K. Kinetics of peripheral hepatitis B virus-specific CD8+ T cells in patients with onset of viral reactivation. J Gastroenterol. 2013;48:728-737. [PMID: 23011082 DOI: 10.1007/s00535-012-0676-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
76 Cangelosi Q, Means SA, Ho H. A multi-scale spatial model of hepatitis-B viral dynamics. PLoS One 2017;12:e0188209. [PMID: 29216213 DOI: 10.1371/journal.pone.0188209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
77 Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, Enomoto M, Inaba M, Nakatani T, Hino M. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol. 2011;46:556-564. [PMID: 21246383 DOI: 10.1007/s00535-010-0367-5] [Cited by in Crossref: 106] [Cited by in F6Publishing: 88] [Article Influence: 10.6] [Reference Citation Analysis]
78 Cheung MC, Agarwal K. Liver abnormalities in the immunosuppressed. Best Practice & Research Clinical Gastroenterology 2013;27:597-618. [DOI: 10.1016/j.bpg.2013.06.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
79 Voican C, Mir O, Loulergue P, Dhooge M, Brezault C, Dréanic J, Chaussade S, Pol S, Coriat R. Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Annals of Oncology 2016;27:2172-83. [DOI: 10.1093/annonc/mdw414] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 8.4] [Reference Citation Analysis]
80 Raouf HE, Yassin AS, Megahed SA, Ashour MS, Mansour TM. Seroprevalence of occult hepatitis B among Egyptian paediatric hepatitis C cancer patients. J Viral Hepat. 2015;22:103-111. [PMID: 24754376 DOI: 10.1111/jvh.12260] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
81 Lee IC, Huang YH, Chu CJ, Lee PC, Lin HC, Lee SD. Hepatitis B virus reactivation after 23 months of rituximab-based chemotherapy in an HBsAg-negative, anti-HBs-positive patient with follicular lymphoma. J Chin Med Assoc. 2010;73:156-160. [PMID: 20231001 DOI: 10.1016/s1726-4901(10)70031-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
82 Sampedro B, Hernández-López C, Ferrandiz JR, Illaro A, Fábrega E, Cuadrado A, Iruzubieta P, Menéndez S, Cabezas J, Crespo J. Computerized physician order entry-based system to prevent HBV reactivation in patients treated with biologic agents: the PRESCRIB project. Hepatology. 2014;60:106-113. [PMID: 24585503 DOI: 10.1002/hep.27103] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
83 Xiong QF, Xiong T, Huang P, Zhong YD, Wang HL, Yang YF. Early predictors of acute hepatitis B progression to liver failure. PLoS One 2018;13:e0201049. [PMID: 30048531 DOI: 10.1371/journal.pone.0201049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Harigai M, Winthrop K, Takeuchi T, Hsieh TY, Chen YM, Smolen JS, Burmester G, Walls C, Wu WS, Dickson C, Liao R, Genovese MC. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. RMD Open. 2020;6. [PMID: 32098857 DOI: 10.1136/rmdopen-2019-001095] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
85 Lledó JL, Fernández C, Gutiérrez ML, Ocaña S. Management of occult hepatitis B virus infection: an update for the clinician. World J Gastroenterol 2011;17:1563-8. [PMID: 21472122 DOI: 10.3748/wjg.v17.i12.1563] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
86 Toka B, Eminler AT, Gönüllü E, Tozlu M, Uslan MI, Parlak E, Karabay O, Koksal AS. Rheumatologists’ awareness of hepatitis B reactivation before immunosuppressive therapy. Rheumatol Int 2019;39:2077-85. [DOI: 10.1007/s00296-019-04437-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
87 Murt A, Elverdi T, Eskazan AE, Salihoglu A, Ar MC, Ongoren S, Baslar Z, Soysal T. Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic country. Ann Hematol 2020;99:2671-7. [PMID: 32737632 DOI: 10.1007/s00277-020-04206-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
88 Ruan J, Sun S, Cheng X, Han P, Zhang Y, Sun D. Mitomycin, 5-fluorouracil, leflunomide, and mycophenolic acid directly promote hepatitis B virus replication and expression in vitro. Virol J 2020;17:89. [PMID: 32611423 DOI: 10.1186/s12985-020-01339-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Yin S, Wang SJ, Gu WY, Zhang Y, Chen LY, Li H. Risk of different precipitating events for progressing to acute-on-chronic liver failure in HBV-related cirrhotic patients. J Dig Dis 2017;18:292-301. [PMID: 28485081 DOI: 10.1111/1751-2980.12480] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
90 Anastasiou OE, Theissen M, Verheyen J, Bleekmann B, Wedemeyer H, Widera M, Ciesek S. Clinical and Virological Aspects of HBV Reactivation: A Focus on Acute Liver Failure. Viruses 2019;11:E863. [PMID: 31527514 DOI: 10.3390/v11090863] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
91 Lawandi A, Cheng MP, Lee TC. Hepatitis B testing practices at a tertiary care centre and their associated costs: A retrospective analysis. PLoS One 2019;14:e0219347. [PMID: 31283801 DOI: 10.1371/journal.pone.0219347] [Reference Citation Analysis]
92 Sperl J, Frankova S, Kieslichova E, Oliverius M, Janousek L, Honsova E, Trunecka P, Spicak J. Urgent Liver Transplantation for Chemotherapy-Induced HBV Reactivation: A Suitable Option in Patients Recently Treated for Malignant Iymphoma. Transplantation Proceedings 2013;45:2834-7. [DOI: 10.1016/j.transproceed.2013.03.047] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
93 Chaulet P. Tuberculosis: a six-month cure. World Health Forum. 1989;10:116-122. [PMID: 2665766 DOI: 10.1016/j.critrevonc.2015.10.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
94 Randall KL. Rituximab in autoimmune diseases. Aust Prescr 2016;39:131-4. [PMID: 27756976 DOI: 10.18773/austprescr.2016.053] [Cited by in Crossref: 39] [Cited by in F6Publishing: 26] [Article Influence: 7.8] [Reference Citation Analysis]
95 Kalyoncu U, Emmungil H, Onat AM, Yılmaz S, Kaşifoglu T, Akar S, İnanç N, Yıldız F, Küçükşahin O, Karadağ Ö, Mercan R, Bes C, Yazısız V, Yılmazer B, Özmen M, Erten Ş, Şenel S, Yazıcı A, Taşçılar K, Kalfa M, Kiraz S, Kısacık B, Pehlivan Y, Kılıç L, Şimşek İ, Çefle A, Akkoç N, Direskeneli H, Erken E, Turgay M, Öztürk MA, Soy M, Aksu K, Dinç A, Ertenli İ. Current antiviral practice and course of Hepatitis B virus infection in inflammatory arthritis: a multicentric observational study (A + HBV study). Eur J Rheumatol 2015;2:149-54. [PMID: 27708953 DOI: 10.5152/eurjrheum.2015.0111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
96 Roche B, Samuel D. The difficulties of managing severe hepatitis B virus reactivation. Liver Int. 2011;31 Suppl 1:104-110. [PMID: 21205146 DOI: 10.1111/j.1478-3231.2010.02396.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
97 Wang HS, Han SB. Management of Hepatitis B in Special Patient Populations. Clinics in Liver Disease 2010;14:505-20. [DOI: 10.1016/j.cld.2010.05.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
98 Salpini R, Piermatteo L, Battisti A, Colagrossi L, Aragri M, Yu La Rosa K, Bertoli A, Saccomandi P, Lichtner M, Marignani M, Maylin S, Delaugerre C, Morisco F, Coppola N, Marrone A, Iapadre N, Cerva C, Aquaro S, Angelico M, Sarmati L, Andreoni M, Verheyen J, Ceccherini-Silberstein F, Levrero M, Perno CF, Belloni L, Svicher V. A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro. Viruses. 2020;12. [PMID: 32102257 DOI: 10.3390/v12020251] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
99 Kennedy PTF, Litwin S, Dolman GE, Bertoletti A, Mason WS. Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks. Viruses 2017;9:E96. [PMID: 28468285 DOI: 10.3390/v9050096] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
100 Tao Y, Wu D, Zhou L, Chen E, Liu C, Tang X, Jiang W, Han N, Li H, Tang H. Present and Future Therapies for Chronic Hepatitis B. Adv Exp Med Biol. 2020;1179:137-186. [PMID: 31741336 DOI: 10.1007/978-981-13-9151-4_6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
101 Chen P, Wang YY, Chen C, Guan J, Zhu HH, Chen Z. The immunological roles in acute-on-chronic liver failure: An update. Hepatobiliary Pancreat Dis Int 2019;18:403-11. [PMID: 31303562 DOI: 10.1016/j.hbpd.2019.07.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
102 Duan BW, Lu SC, Wang ML, Liu JN, Chi P, Lai W, Wu JS, Guo QL, Lin DD, Liu Y. Liver transplantation in acute-on-chronic liver failure patients with high model for end-stage liver disease (MELD) scores: a single center experience of 100 consecutive cases. J Surg Res. 2013;183:936-943. [PMID: 23558257 DOI: 10.1016/j.jss.2013.03.008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 5.5] [Reference Citation Analysis]
103 Wang B, Mufti G, Agarwal K. Reactivation of hepatitis B virus infection in patients with hematologic disorders. Haematologica. 2019;104:435-443. [PMID: 30733266 DOI: 10.3324/haematol.2018.210252] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
104 Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology. 2015;479-480:672-686. [PMID: 25759099 DOI: 10.1016/j.virol.2015.02.031] [Cited by in Crossref: 398] [Cited by in F6Publishing: 362] [Article Influence: 66.3] [Reference Citation Analysis]
105 Weitzel T, Rodríguez F, Noriega LM, Marcotti A, Duran L, Palavecino C, Porte L, Aguilera X, Wolff M, Cortes CP. Hepatitis B and C virus infection among HIV patients within the public and private healthcare systems in Chile: A cross-sectional serosurvey. PLoS One 2020;15:e0227776. [PMID: 31917810 DOI: 10.1371/journal.pone.0227776] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
106 Vassilopoulos D. Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? Yes. Eur J Intern Med. 2011;22:572-575. [PMID: 22075282 DOI: 10.1016/j.ejim.2011.09.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
107 Abdelaal R, Yanny B, El Kabany M. HBV/HCV Coinfection in the Era of HCV-DAAs. Clin Liver Dis 2019;23:463-72. [PMID: 31266620 DOI: 10.1016/j.cld.2019.04.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
108 Lee J, Park JY, Kim DG, Lee JY, Kim BS, Kim MS, Il Kim S, Kim YS, Huh KH. Effects of rituximab dose on hepatitis B reactivation in patients with resolved infection undergoing immunologic incompatible kidney transplantation. Sci Rep 2018;8. [DOI: 10.1038/s41598-018-34111-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
109 Yanny BT, Latt NL, Saab S, Han S, Choi G, Kramer J, Sahota AK. Risk of Hepatitis B Virus Reactivation Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection. J Clin Gastroenterol 2018;52:908-12. [PMID: 29334502 DOI: 10.1097/MCG.0000000000000986] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
110 Gitto S, Cursaro C, Bartoli A, Margotti M, Andreone P. Hepatitis C: clinical management and debated issues. Minerva Med 2021;112:228-37. [PMID: 33319975 DOI: 10.23736/S0026-4806.20.07208-0] [Reference Citation Analysis]
111 Burton MJ, Curtis JR, Yang S, Chen L, Singh JA, Mikuls TR, Winthrop KL, Baddley JW. Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study. Arthritis Res Ther 2015;17:136. [PMID: 26001631 DOI: 10.1186/s13075-015-0628-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
112 Mori S. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Mod Rheumatol. 2011;21:621-627. [PMID: 21528424 DOI: 10.1007/s10165-011-0458-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
113 Loggi E, Gitto S, Galli S, Minichiello M, Conti F, Grandini E, Scuteri A, Vitale G, Di Donato R, Cursaro C. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice. J Clin Virol. 2017;93:66-70. [PMID: 28654775 DOI: 10.1016/j.jcv.2017.05.021] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
114 Gopal K, Min AD. Chemoprevention of Patients with Hepatitis B Receiving Chemotherapy or Bone Marrow Transplant. Curr Hepatitis Rep 2010;9:178-86. [DOI: 10.1007/s11901-010-0048-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
115 Li J, Huang B, Li Y, Zheng D, Zhou Z, Liu J. Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regimens followed by autologous stem cell transplant. Leuk Lymphoma. 2015;56:1710-1717. [PMID: 25098429 DOI: 10.3109/10428194.2014.941833] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
116 Vitrone M, Iossa D, Rinaldi L, Pafundi PC, Molaro R, Parrella A, Andini R, Ragone E, Maiello C, Zampino R, Durante-Mangoni E. Hepatitis B virus reactivation after heart transplant: Incidence and clinical impact. J Clin Virol 2017;96:54-9. [PMID: 28964958 DOI: 10.1016/j.jcv.2017.09.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Lin GN, Peng JW, Xiao JJ, Liu DY, Xia ZJ. Hepatitis B virus reactivation in hepatitis B surface antigen seropositive patients with metastatic non-small cell lung cancer receiving cytotoxic chemotherapy: the efficacy of preemptive lamivudine and identification of risk factors. Med Oncol 2014;31:119. [PMID: 25023055 DOI: 10.1007/s12032-014-0119-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
118 Anastasiou OE, Widera M, Korth J, Kefalakes H, Katsounas A, Hilgard G, Gerken G, Canbay A, Ciesek S, Verheyen J. Clinical patterns associated with the concurrent detection of anti-HBs and HBV DNA. J Med Virol 2018;90:282-90. [PMID: 28892166 DOI: 10.1002/jmv.24942] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
119 Koutsianas C, Thomas K, Vassilopoulos D. Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations. Ther Adv Musculoskelet Dis. 2020;12:1759720X20912646. [PMID: 32206094 DOI: 10.1177/1759720x20912646] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
120 Liu Z, Jiang L, Liang G, Song E, Jiang W, Zheng Y, Gong C. Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta-analysis of prophylaxis management. J Viral Hepat 2017;24:561-72. [PMID: 28072494 DOI: 10.1111/jvh.12672] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
121 Kostyusheva A, Kostyushev D, Brezgin S, Volchkova E, Chulanov V. Clinical Implications of Hepatitis B Virus RNA and Covalently Closed Circular DNA in Monitoring Patients with Chronic Hepatitis B Today with a Gaze into the Future: The Field Is Unprepared for a Sterilizing Cure. Genes (Basel) 2018;9:E483. [PMID: 30301171 DOI: 10.3390/genes9100483] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
122 Chen KL, Chen J, Rao HL, Guo Y, Huang HQ, Zhang L, Shao JY, Lin TY, Jiang WQ, Zou DH, Hu LY, Wirian ML, Cai QQ. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival. Chin J Cancer 2015;34:225-34. [PMID: 26058465 DOI: 10.1186/s40880-015-0015-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
123 Urata Y, Uesato R, Tanaka D, Kowatari K, Nitobe T, Nakamura Y, Motomura S. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Modern Rheumatology 2014;21:16-23. [DOI: 10.3109/s10165-010-0337-z] [Cited by in Crossref: 65] [Cited by in F6Publishing: 33] [Article Influence: 9.3] [Reference Citation Analysis]
124 Unger JM, Hershman DL, Arnold KB, Loomba R, Chugh R, Hwang JP, O'Rourke MA, Bhadkamkar NA, Wang LX, Siegel AB, Cooley TP, Berenberg JL, Bridges BB, Ramsey SD. Stepwise development of a cancer care delivery research study to evaluate the prevalence of virus infections in cancer patients. Future Oncol 2016;12:1219-31. [PMID: 26952901 DOI: 10.2217/fon-2015-0076] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
125 Ni YH. Natural history of hepatitis B virus infection: pediatric perspective. J Gastroenterol. 2011;46:1-8. [PMID: 20812021 DOI: 10.1007/s00535-010-0304-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
126 Deroux A, Larrat S, Hilleret MN, Baccard M, Qin W, Billet G, Zaoui P, Morand P. Case report: detection of a hepatitis B surface antigen variant emerging in an elderly patient after an ischemic cerebral vascular accident. J Med Virol 2012;84:1897-900. [PMID: 23080493 DOI: 10.1002/jmv.23420] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
127 Terrier B, Pol S, Thibault V, Gottenberg J, Cacoub P. Prise en charge du risque de réactivation du virus de l’hépatite B chez les patients traités par immunosuppresseurs et immunomodulateurs en médecine interne : données de l’enquête REACTI-B et proposition d’un algorithme de prise en charge. La Revue de Médecine Interne 2012;33:4-12. [DOI: 10.1016/j.revmed.2011.07.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
128 Tsai WL, Sun WC, Cheng JS. Chronic Hepatitis B with Spontaneous Severe Acute Exacerbation. Int J Mol Sci. 2015;16:28126-28145. [PMID: 26703566 DOI: 10.3390/ijms161226087] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
129 Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, Kann M, Knolle PA, Benkirane M, Durantel D, Michel M, Autran B, Cosset F, Strick-marchand H, Trépo C, Kao J, Carrat F, Lacombe K, Schinazi RF, Barré-sinoussi F, Delfraissy J, Zoulim F. Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure. Gut 2015;64:1314-26. [DOI: 10.1136/gutjnl-2014-308943] [Cited by in Crossref: 186] [Cited by in F6Publishing: 168] [Article Influence: 31.0] [Reference Citation Analysis]
130 Liu CJ, Chuang WL, Sheen IS, Wang HY, Chen CY, Tseng KC, Chang TT, Massetto B, Yang JC, Yun C, Knox SJ, Osinusi A, Camus G, Jiang D, Brainard DM, McHutchison JG, Hu TH, Hsu YC, Lo GH, Chu CJ, Chen JJ, Peng CY, Chien RN, Chen PJ. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. Gastroenterology 2018;154:989-97. [PMID: 29174546 DOI: 10.1053/j.gastro.2017.11.011] [Cited by in Crossref: 70] [Cited by in F6Publishing: 59] [Article Influence: 17.5] [Reference Citation Analysis]
131 De Monte A, Courjon J, Anty R, Cua E, Naqvi A, Mondain V, Cottalorda J, Ollier L, Giordanengo V. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol. 2016;78:27-30. [PMID: 26967675 DOI: 10.1016/j.jcv.2016.02.026] [Cited by in Crossref: 92] [Cited by in F6Publishing: 72] [Article Influence: 18.4] [Reference Citation Analysis]
132 Adenlewo OJ, Adeosun PO, Fatusi OA. Medical and dental students' attitude and practice of prevention strategies against hepatitis B virus infection in a Nigerian university. Pan Afr Med J 2017;28:33. [PMID: 29138669 DOI: 10.11604/pamj.2017.28.33.11662] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
133 Sebastiani M, Atzeni F, Milazzo L, Quartuccio L, Scirè C, Gaeta GB, Lapadula G, Armignacco O, Tavio M, Olivieri I, Meroni P, Bazzichi L, Grassi W, Mathieu A, Mastroianni C, Sagnelli E, Santantonio T, Uberti Foppa C, Puoti M, Sarmati L, Airò P, Epis OM, Scrivo R, Gargiulo M, Riva A, Manfredi A, Ciancio G, Zehender G, Taliani G, Meroni L, Sollima S, Sarzi-puttini P, Galli M. Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. Joint Bone Spine 2017;84:525-30. [DOI: 10.1016/j.jbspin.2017.05.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
134 Ryu HH, Lee EY, Shin K, Choi IA, Lee YJ, Yoo B, Park MC, Park YB, Bae SC, Yoo WH. Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: a retrospective analysis of 49 cases. Clin Rheumatol. 2012;31:931-936. [PMID: 22349880 DOI: 10.1007/s10067-012-1960-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 4.8] [Reference Citation Analysis]
135 Clarke WT, Amin SS, Papamichael K, Feuerstein JD, Cheifetz AS. Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAg−) on anti-TNF therapy have a low rate of reactivation. Clinical Immunology 2018;191:59-62. [DOI: 10.1016/j.clim.2018.03.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
136 Yang YW, Chen CC, Yang CY, Lee CY, Yang HC, Chiang BL, Chuang YH, Wu TE, Lai HS, Tsai MK. Dynamics of cellular immune responses in recipients of renal allografts positive for hepatitis B surface antigen. J Formos Med Assoc 2021:S0929-6646(21)00338-7. [PMID: 34294497 DOI: 10.1016/j.jfma.2021.07.008] [Reference Citation Analysis]
137 Tien YC, Yen HH, Li CF, Liu MP, Hsue YT, Hung MH, Chiu YM. Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study. Arthritis Res Ther 2018;20:246. [PMID: 30382902 DOI: 10.1186/s13075-018-1748-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
138 Marrone A, Capoluongo N, D'Amore C, Pisaturo M, Esposito M, Guastafierro S, Siniscalchi I, Macera M, Boemio A, Onorato L, Rinaldi L, Minichini C, Adinolfi LE, Sagnelli E, Mastrullo L, Coppola N. Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy. J Viral Hepat. 2018;25:198-204. [PMID: 29029365 DOI: 10.1111/jvh.12802] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
139 Lei Z, Xia Y, Si A, Wang K, Li J, Yan Z, Yang T, Wu D, Wan X, Zhou W, Liu J, Wang H, Cong W, Wu M, Pawlik TM, Lau WY, Shen F. Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection. J Hepatol. 2018;68:655-662. [PMID: 29155069 DOI: 10.1016/j.jhep.2017.11.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
140 Ramos-casals M. Are TNF blockers safe for patients with hepatitis B virus infection? Nat Rev Rheumatol 2010;6:618-20. [DOI: 10.1038/nrrheum.2010.156] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
141 Seeger C. Control of viral transcripts as a concept for future HBV therapies. Curr Opin Virol. 2018;30:18-23. [PMID: 29453098 DOI: 10.1016/j.coviro.2018.01.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
142 Buti M, Manzano ML, Morillas RM, García-Retortillo M, Martín L, Prieto M, Gutiérrez ML, Suárez E, Gómez Rubio M, López J, Castillo P, Rodríguez M, Zozaya JM, Simón MA, Morano LE, Calleja JL, Yébenes M, Esteban R. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. PLoS One 2017;12:e0184550. [PMID: 28898281 DOI: 10.1371/journal.pone.0184550] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
143 Shiah HS, Chen CY, Dai CY, Hsiao CF, Lin YJ, Su WC, Chang JY, Whang-Peng J, Lin PW, Huang JD. Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. Aliment Pharmacol Ther. 2013;37:62-73. [PMID: 23134470 DOI: 10.1111/apt.12132] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 5.3] [Reference Citation Analysis]
144 Yang Y, Yan Y, Chen Z, Hu J, Wang K, Tang N, Li X, Zhou Z. Histone Deacetylase Inhibitors Romidepsin and Vorinostat Promote Hepatitis B Virus Replication by Inducing Cell Cycle Arrest. J Clin Transl Hepatol 2021;9:160-8. [PMID: 34007797 DOI: 10.14218/JCTH.2020.00105] [Reference Citation Analysis]
145 Liu WP, Xiao XB, Xue M, Wang GQ, Wang XP, Song YQ, Zhu J. Prophylactic Use of Entecavir for Lymphoma Patients With Past Hepatitis B Virus Infection: A Randomized Controlled Trial. Clinical Lymphoma Myeloma and Leukemia 2019;19:103-8. [DOI: 10.1016/j.clml.2018.11.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
146 Cannizzaro MV, Franceschini C, Esposito M, Bianchi L, Giunta A. Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management. Psoriasis (Auckl) 2017;7:35-40. [PMID: 29387606 DOI: 10.2147/PTT.S108209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
147 Block TM, Rawat S, Brosgart CL. Chronic hepatitis B: A wave of new therapies on the horizon. Antiviral Res. 2015;121:69-81. [PMID: 26112647 DOI: 10.1016/j.antiviral.2015.06.014] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 8.3] [Reference Citation Analysis]
148 Block TM, Gish R, Guo H, Mehta A, Cuconati A, Thomas London W, Guo JT. Chronic hepatitis B: what should be the goal for new therapies? Antiviral Res. 2013;98:27-34. [PMID: 23391846 DOI: 10.1016/j.antiviral.2013.01.006] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 10.3] [Reference Citation Analysis]
149 Shi Y, Zheng M. Hepatitis B virus persistence and reactivation. BMJ. 2020;370:m2200. [PMID: 32873599 DOI: 10.1136/bmj.m2200] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
150 Rehermann B, Bertoletti A. Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatology 2015;61:712-21. [PMID: 25048716 DOI: 10.1002/hep.27323] [Cited by in Crossref: 102] [Cited by in F6Publishing: 97] [Article Influence: 17.0] [Reference Citation Analysis]
151 Louthrenoo W. Treatment considerations in patients with concomitant viral infection and autoimmune rheumatic diseases. Best Practice & Research Clinical Rheumatology 2015;29:319-42. [DOI: 10.1016/j.berh.2015.05.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
152 Lee PC, Chao Y, Chen MH, Lan KH, Lee IC, Hou MC, Huang YH. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer 2020;8:e001072. [PMID: 32863270 DOI: 10.1136/jitc-2020-001072] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 12.0] [Reference Citation Analysis]
153 Sato A, Ishii T, Sano F, Yamada T, Takahashi H, Matsumoto N. Severe de novo Hepatitis B Recovered from Late-Onset Liver Insufficiency with Prolonged Ascites and Hypoalbuminemia due to Hepatitis B Virus Genotype Bj with Precore Mutation. Case Rep Gastroenterol 2016;10:553-9. [PMID: 27920641 DOI: 10.1159/000450543] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
154 Obara N, Inoue J, Endo H, Kakazu E, Ninomiya M, Iwata T, Sano A, Tsuruoka M, Masamune A. Spontaneous reactivation of hepatitis B virus with S gene mutations in an elderly patient with diabetic nephropathy. Clin J Gastroenterol 2020;13:914-9. [PMID: 32519312 DOI: 10.1007/s12328-020-01149-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Pauly MP, Tucker LY, Szpakowski JL, Ready JB, Baer D, Hwang J, Lok AS. Incidence of Hepatitis B Virus Reactivation and Hepatotoxicity in Patients Receiving Long-term Treatment With Tumor Necrosis Factor Antagonists. Clin Gastroenterol Hepatol 2018; 16: 1964-1973. e1. [PMID: 29702293 DOI: 10.1016/j.cgh.2018.04.033] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
156 Kimura M, Nishikawa K, Sakamaki H, Mizokami M, Kimura K. Reduced therapeutic effect of antiviral drugs in patients with hepatitis B virus reactivation after hematopoietic stem cell transplantation. Hepatol Res 2018;48:469-78. [PMID: 29235226 DOI: 10.1111/hepr.13044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
157 Tseng CM, Chen TB, Hsu YC, Chang CY, Lin JT, Mo LR. Comparative effectiveness of nucleos(t)ide analogues in chronic hepatitis B patients undergoing cytotoxic chemotherapy. Asia Pac J Clin Oncol 2016;12:421-9. [PMID: 27435683 DOI: 10.1111/ajco.12520] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
158 Mao S, Wang M, Ou X, Sun D, Cheng A, Zhu D, Chen S, Jia R, Liu M, Sun K, Yang Q, Wu Y, Zhao X, Chen X. Virologic and Immunologic Characteristics in Mature Ducks with Acute Duck Hepatitis A Virus 1 Infection. Front Immunol 2017;8:1574. [PMID: 29201029 DOI: 10.3389/fimmu.2017.01574] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
159 Loomba R, Liang TJ. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology. 2017;152:1297-1309. [PMID: 28219691 DOI: 10.1053/j.gastro.2017.02.009] [Cited by in Crossref: 241] [Cited by in F6Publishing: 191] [Article Influence: 60.3] [Reference Citation Analysis]
160 Sagnelli C, Pisaturo M, Calò F, Martini S, Sagnelli E, Coppola N. Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention. World J Gastroenterol 2019;25:3299-312. [PMID: 31341357 DOI: 10.3748/wjg.v25.i26.3299] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
161 Hussain S, Jhaj R, Ahsan S, Ahsan M, Bloom RE, Jafri SM. Bortezomib induced hepatitis B reactivation. Case Rep Med 2014;2014:964082. [PMID: 24876846 DOI: 10.1155/2014/964082] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
162 Lumley SF, McNaughton AL, Klenerman P, Lythgoe KA, Matthews PC. Hepatitis B Virus Adaptation to the CD8+ T Cell Response: Consequences for Host and Pathogen. Front Immunol 2018;9:1561. [PMID: 30061882 DOI: 10.3389/fimmu.2018.01561] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
163 Lei T, Tan F, Hou Z, Liu P, Zhao X, Liu H. Hepatitis B Virus Reactivation in Gastrointestinal Stromal Tumor Patients Treated With Imatinib. Front Oncol 2020;10:596500. [PMID: 33552970 DOI: 10.3389/fonc.2020.596500] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 Yeo D, Hossain I, Lim ST, Farid M, Tao M, Quek R, Tang T, Chan A. Management of hepatitis B reactivation in lymphoma patients on rituximab with past hepatitis B exposure: An observational study. J Oncol Pharm Pract 2019;25:1042-52. [PMID: 29554828 DOI: 10.1177/1078155218763039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
165 Hsu PI, Lai KH, Cheng JS, Kao SS, Li YR, Sun WC, Chen WC, Lin KH, Shin CA, Chiang PH, Li YD, Ou WT, Chen HC, Yu HC. Prevention of acute exacerbation of chronic hepatitis B infection in cancer patients receiving chemotherapy in a hepatitis B virus endemic area. Hepatology. 2015;62:387-396. [PMID: 26041578 DOI: 10.1002/hep.27843] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
166 Delladetsima I, Papatheodoridis GV, Tiniakos DG, Hatzakis A, Tassopoulos NC. Significance of liver histology in HBsAg-positive, IgM anti-HBc-negative acute hepatitis B virus-related hepatitis. Histopathology 2012;61:881-8. [PMID: 22882633 DOI: 10.1111/j.1365-2559.2012.04294.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
167 Mahale P, Kontoyiannis DP, Chemaly RF, Jiang Y, Hwang JP, Davila M, Torres HA. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol. 2012;57:1177-1185. [PMID: 22871500 DOI: 10.1016/j.jhep.2012.07.031] [Cited by in Crossref: 78] [Cited by in F6Publishing: 66] [Article Influence: 8.7] [Reference Citation Analysis]
168 Federico A, Brancaccio G, Dallio M, Iodice P, Fabozzi A, Del Prete S, Ciardiello F, Loguercio C, Gaeta GB. Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required? Dig Liver Dis 2017;49:197-201. [PMID: 27899262 DOI: 10.1016/j.dld.2016.11.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
169 Mallet V, Hamed K, Schwarzinger M. Prognosis of patients with chronic hepatitis B in France (2008–2013): A nationwide, observational and hospital-based study. Journal of Hepatology 2017;66:514-20. [DOI: 10.1016/j.jhep.2016.10.031] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
170 Wong F. Renal diseases and the liver. Clin Liver Dis 2011;15:39-53. [PMID: 21111992 DOI: 10.1016/j.cld.2010.09.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
171 Nishikawa K, Kimura K, Kanda Y, Sugiyama M, Kakihana K, Doki N, Ohashi K, Bae SK, Takahashi K, Ishihara Y, Mizuno I, Onishi Y, Onozawa M, Onizuka M, Yamamoto M, Ishikawa T, Inoue K, Kusumoto S, Hashino S, Saito H, Kanto T, Sakamaki H, Mizokami M. A prospective trial of vaccine to prevent hepatitis B virus reactivation after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2020;55:1388-1398. [PMID: 32071416 DOI: 10.1038/s41409-020-0833-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
172 Takahashi A, Abe K, Yokokawa J, Iwadate H, Kobayashi H, Watanabe H, Irisawa A, Ohira H. Clinical features of liver dysfunction in collagen diseases. Hepatol Res 2010;40:1092-7. [PMID: 20880057 DOI: 10.1111/j.1872-034X.2010.00707.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 11] [Article Influence: 4.2] [Reference Citation Analysis]
173 Liu S, Lai J, Lyu N, Xie Q, Cao H, Chen D, He M, Zhang B, Zhao M. Effects of Antiviral Therapy on HBV Reactivation and Survival in Hepatocellular Carcinoma Patients Undergoing Hepatic Artery Infusion Chemotherapy. Front Oncol 2020;10:582504. [PMID: 33614477 DOI: 10.3389/fonc.2020.582504] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
174 Li H, Chen LY, Zhang NN, Li ST, Zeng B, Pavesi M, Amorós À, Mookerjee RP, Xia Q, Xue F, Ma X, Hua J, Sheng L, Qiu DK, Xie Q, Foster GR, Dusheiko G, Moreau R, Gines P, Arroyo V, Jalan R. Characteristics, Diagnosis and Prognosis of Acute-on-Chronic Liver Failure in Cirrhosis Associated to Hepatitis B. Sci Rep. 2016;6:25487. [PMID: 27146801 DOI: 10.1038/srep25487] [Cited by in Crossref: 76] [Cited by in F6Publishing: 64] [Article Influence: 15.2] [Reference Citation Analysis]
175 Watanabe T, Tanaka Y. Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy. Hepatol Res. 2013;43:113-121. [PMID: 23186317 DOI: 10.1111/hepr.12014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
176 Feuchtenberger M, Schäfer A, Philipp Nigg A, Rupert Kraus M. Hepatitis B Serology in Patients with Rheumatic Diseases. Open Rheumatol J 2016;10:39-48. [PMID: 27708728 DOI: 10.2174/1874312901610010039] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
177 Plachouri KM, Georgiou S. Special aspects of biologics treatment in psoriasis: management in pregnancy, lactation, surgery, renal impairment, hepatitis and tuberculosis. J Dermatolog Treat 2019;30:668-73. [PMID: 30428753 DOI: 10.1080/09546634.2018.1544413] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
178 Campos-Valdez M, Monroy-Ramírez HC, Armendáriz-Borunda J, Sánchez-Orozco LV. Molecular Mechanisms during Hepatitis B Infection and the Effects of the Virus Variability. Viruses 2021;13:1167. [PMID: 34207116 DOI: 10.3390/v13061167] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
179 Deray G, Buti M, Gane E, Jia J, Chan HLY, Craxi A, Piratvisuth T, Pol S. Hepatitis B Virus Infection and the Kidney: Renal Abnormalities in HBV Patients, Antiviral Drugs Handling, and Specific Follow-Up. Advances in Hepatology 2015;2015:1-11. [DOI: 10.1155/2015/596829] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
180 Kim YM, Jeong S, Kim J, Lee SH, Hwang JH, Park YS, Kim N, Lee JS, Kim HY, Lee DH. Chronic hepatitis B, non-Hodgkin's lymphoma, and effect of prophylactic antiviral therapy. Journal of Clinical Virology 2011;51:241-5. [DOI: 10.1016/j.jcv.2011.05.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
181 Zoulim F, Lebossé F, Levrero M. Current treatments for chronic hepatitis B virus infections. Curr Opin Virol 2016;18:109-16. [PMID: 27318098 DOI: 10.1016/j.coviro.2016.06.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 8.8] [Reference Citation Analysis]
182 Tan J, Zhou J, Zhao P, Wei J. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol. 2012;31:1169-1175. [PMID: 22544263 DOI: 10.1007/s10067-012-1988-2] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
183 Choi J, Lim YS. Characteristics, Prevention, and Management of Hepatitis B Virus (HBV) Reactivation in HBV-Infected Patients Who Require Immunosuppressive Therapy. J Infect Dis. 2017;216:S778-S784. [PMID: 29156044 DOI: 10.1093/infdis/jix178] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
184 Pondé RA. Acute hepatitis B virus infection or acute exacerbation of chronic hepatitis B infection: the differential serological diagnosis. Eur J Clin Microbiol Infect Dis 2016;35:29-40. [PMID: 26581426 DOI: 10.1007/s10096-015-2522-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
185 Jang JW, Kim YW, Lee SW, Kwon JH, Nam SW, Bae SH, Choi JY, Yoon SK, Chung KW. Reactivation of hepatitis B virus in HBsAg-negative patients with hepatocellular carcinoma. PLoS One. 2015;10:e0122041. [PMID: 25894607 DOI: 10.1371/journal.pone.0122041] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
186 Bojito-Marrero L, Pyrsopoulos N. Hepatitis B and Hepatitis C Reactivation in the Biologic Era. J Clin Transl Hepatol. 2014;2:240-246. [PMID: 26355300 DOI: 10.14218/jcth.2014.00033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
187 Di Bisceglie AM, Lombardero M, Teckman J, Roberts L, Janssen HL, Belle SH, Hoofnagle JH; Hepatitis B Research Network (HBRN). Determination of hepatitis B phenotype using biochemical and serological markers. J Viral Hepat. 2017;24:320-329. [PMID: 27917600 DOI: 10.1111/jvh.12643] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
188 Atteya A, Ahmad A, Daghstani D, Mushtaq K, Yassin MA. Evaluation of Hepatitis B Reactivation Among Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. Cancer Control 2020;27:1073274820976594. [PMID: 33297765 DOI: 10.1177/1073274820976594] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
189 Indolfi G, Nesi A, Resti M. Treatment of chronic hepatitis B and C in children. Future Virology 2012;7:955-72. [DOI: 10.2217/fvl.12.94] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
190 Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, Liu CY, Yang MH, Tzeng CH, Lee PC, Lin HC, Lee SD. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol. 2013;31:2765-2772. [PMID: 23775967 DOI: 10.1200/jco.2012.48.5938] [Cited by in Crossref: 221] [Cited by in F6Publishing: 82] [Article Influence: 27.6] [Reference Citation Analysis]
191 Ren Y, Liu L, Li Y, Yang F, He Y, Zhu Y, Hu X, Lin S. Development and validation of a scoring system to predict progression to acute-on-chronic liver failure in patients with acute exacerbation of chronic hepatitis B. Hepatol Res. 2018;48:692-700. [PMID: 29336092 DOI: 10.1111/hepr.13062] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
192 Houssou B, Massi RM, Camara M, Mifdal H, Nourichafi N, Zafad S, Oukkache B. [Reactivation of hepatitis B virus in a patient treated for non-Hodgkin B diffuse large cell lymphoma with rituximab: about a case]. Pan Afr Med J 2015;22:22. [PMID: 26664523 DOI: 10.11604/pamj.2015.22.22.7579] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
193 Terrier B, Cacoub P. Virus de l’hépatite B, manifestations extrahépatiques immunologiques et risque de réactivation virale. La Revue de Médecine Interne 2011;32:622-7. [DOI: 10.1016/j.revmed.2010.08.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
194 Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol 2014;11:209-19. [PMID: 24247262 DOI: 10.1038/nrgastro.2013.216] [Cited by in Crossref: 155] [Cited by in F6Publishing: 131] [Article Influence: 19.4] [Reference Citation Analysis]
195 Martinez MG, Testoni B, Zoulim F. Biological basis for functional cure of chronic hepatitis B. J Viral Hepat 2019;26:786-94. [DOI: 10.1111/jvh.13090] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
196 Hoffmann CJ, Dayal D, Cheyip M, McIntyre JA, Gray GE, Conway S, Martinson NA. Prevalence and associations with hepatitis B and hepatitis C infection among HIV-infected adults in South Africa. Int J STD AIDS 2012;23:e10-3. [PMID: 23104758 DOI: 10.1258/ijsa.2009.009340] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
197 Downs LO, McNaughton AL, de Cesare M, Ansari MA, Martin J, Woodrow C, Bowden R, Collier J, Barnes E, Matthews PC. Case Report: Application of hepatitis B virus (HBV) deep sequencing to distinguish between acute and chronic infection. Wellcome Open Res 2020;5:240. [PMID: 33458253 DOI: 10.12688/wellcomeopenres.16157.2] [Reference Citation Analysis]
198 Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 221-244. e3. [PMID: 25447852 DOI: 10.1053/j.gastro.2014.10.038] [Cited by in Crossref: 274] [Cited by in F6Publishing: 231] [Article Influence: 39.1] [Reference Citation Analysis]
199 Nard FD, Todoerti M, Grosso V, Monti S, Breda S, Rossi S, Montecucco C, Caporali R. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. World J Hepatol 2015;7:344-61. [PMID: 25848463 DOI: 10.4254/wjh.v7.i3.344] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 7.7] [Reference Citation Analysis]
200 Pisaturo M, Di Caprio G, Calò F, Portunato F, Martini S, Coppola N. Management of HBV reactivation in non-oncological patients. Expert Rev Anti Infect Ther 2018;16:611-24. [PMID: 30058401 DOI: 10.1080/14787210.2018.1505501] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
201 Makara M, Horváth G, Gervain J, Pár A, Szalay F, Telegdy L, Tornai I, Újhelyi E, Hunyady B. Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis. Orvosi Hetilap 2012;153:375-94. [DOI: 10.1556/oh.2012.29338] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
202 Aljaberi N, Ghulam E, Smitherman EA, Favier L, Dykes DMH, Danziger-Isakov LA, Brady RC, Huggins J. Maintaining Hepatitis B Protection in Immunocompromised Pediatric Rheumatology and Inflammatory Bowel Disease Patients. J Rheumatol. 2020;. [PMID: 32739895 DOI: 10.3899/jrheum.200283] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
203 Chiu HY, Chiu YM, Chang Liao NF, Chi CC, Tsai TF, Hsieh CY, Hsieh TY, Lai KL, Chiu TM, Wu NL, Hui RC, Lee CN, Wang TS, Chen PH, Yang CC, Huang YH. Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biological agent: A nine-year multicenter cohort study. J Am Acad Dermatol. 2019;. [PMID: 31821860 DOI: 10.1016/j.jaad.2019.12.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
204 Chen YM, Chen HH, Huang WN, Chen YH, Hsieh TY, Yang SS, Lan JL, Chen DY. Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: A long-term, real-world observation. Int J Rheum Dis 2019;22:1145-51. [PMID: 31117160 DOI: 10.1111/1756-185X.13582] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
205 Kusumoto S, Tanaka Y, Suzuki R, Watanabe T, Nakata M, Takasaki H, Fukushima N, Fukushima T, Moriuchi Y, Itoh K, Nosaka K, Choi I, Sawa M, Okamoto R, Tsujimura H, Uchida T, Suzuki S, Okamoto M, Takahashi T, Sugiura I, Onishi Y, Kohri M, Yoshida S, Sakai R, Kojima M, Takahashi H, Tomita A, Maruyama D, Atsuta Y, Tanaka E, Suzuki T, Kinoshita T, Ogura M, Mizokami M, Ueda R. Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study. Clin Infect Dis. 2015;61:719-729. [PMID: 25935551 DOI: 10.1093/cid/civ344] [Cited by in Crossref: 93] [Cited by in F6Publishing: 80] [Article Influence: 15.5] [Reference Citation Analysis]
206 Kusumoto S, Tanaka Y, Suzuki R, Watanabe T, Nakata M, Sakai R, Fukushima N, Fukushima T, Moriuchi Y, Itoh K, Nosaka K, Choi I, Sawa M, Okamoto R, Tsujimura H, Uchida T, Suzuki S, Okamoto M, Takahashi T, Sugiura I, Onishi Y, Kohri M, Yoshida S, Kojima M, Takahashi H, Tomita A, Atsuta Y, Maruyama D, Tanaka E, Suzuki T, Kinoshita T, Ogura M, Ueda R, Mizokami M. Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphoma. J Hepatol 2020;73:285-93. [PMID: 32194183 DOI: 10.1016/j.jhep.2020.03.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
207 Wang Q, Klenerman P, Semmo N. Significance of anti-HBc alone serological status in clinical practice. The Lancet Gastroenterology & Hepatology 2017;2:123-34. [DOI: 10.1016/s2468-1253(16)30076-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 3] [Article Influence: 5.3] [Reference Citation Analysis]
208 Arora A, Anand AC, Kumar A, Singh SP, Aggarwal R, Dhiman RK, Aggarwal S, Alam S, Bhaumik P, Dixit VK, Goel A, Goswami B, Kumar A, Kumar M, Madan K, Murugan N, Nagral A, Puri AS, Rao PN, Saraf N, Saraswat VA, Sehgal S, Sharma P, Shenoy KT, Wadhawan M; Members of the INASL taskforce on Hepatitis B. INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy, Biologicals, Immunosupressants, or Corticosteroids. J Clin Exp Hepatol 2018;8:403-31. [PMID: 30568345 DOI: 10.1016/j.jceh.2018.06.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
209 Pei R, Grund S, Verheyen J, Esser S, Chen X, Lu M. Spontaneous reactivation of hepatitis B virus replication in an HIV coinfected patient with isolated anti-Hepatitis B core antibodies. Virol J. 2014;11:9. [PMID: 24444423 DOI: 10.1186/1743-422x-11-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 2.9] [Reference Citation Analysis]
210 Coffin CS, Fung SK, Ma MM; Canadian Association for the Study of the Liver. Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol 2012;26:917-38. [PMID: 23248795 DOI: 10.1155/2012/506819] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
211 Shih CA, Chen WC. Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy. World J Clin Cases 2021;9:5769-81. [PMID: 34368296 DOI: 10.12998/wjcc.v9.i21.5769] [Reference Citation Analysis]
212 Cambier ML, Canestri A, Lependeven C, Peltier J, Mesnard L, Dahan K. Hepatitis B virus reactivation during belatacept treatment after kidney transplantation. Transpl Infect Dis 2019;21:e13170. [PMID: 31505095 DOI: 10.1111/tid.13170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
213 Aygen B, Demir AM, Gümüş M, Karabay O, Kaymakoğlu S, Köksal AŞ, Köksal İ, Örmeci N, Tabak F. Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report. Turk J Gastroenterol 2018;29:259-69. [PMID: 29755010 DOI: 10.5152/tjg.2018.18263] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
214 Tu T, Budzinska MA, Shackel NA, Jilbert AR. Conceptual models for the initiation of hepatitis B virus-associated hepatocellular carcinoma. Liver Int 2015;35:1786-800. [PMID: 25640596 DOI: 10.1111/liv.12773] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
215 Inoue J, Kondo Y, Wakui Y, Kogure T, Morosawa T, Fujisaka Y, Umetsu T, Takai S, Nakamura T, Shimosegawa T. Reactivation of resolved hepatitis B virus infection with immune escape mutations after long-term corticosteroid therapy. Clin J Gastroenterol 2016;9:93-8. [PMID: 26919858 DOI: 10.1007/s12328-016-0631-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
216 Han L, Zhou J, Zhou K, Zhu X, Zhao L, Fang B, Yin Q, Wei X, Zhou H, Li L, Xu B, Zhang J, Song Y, Gao Q. Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus. J Immunother Cancer 2020;8:e000927. [PMID: 32792360 DOI: 10.1136/jitc-2020-000927] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
217 Huang YW, Chung RT. Management of hepatitis B reactivation in patients receiving cancer chemotherapy. Therap Adv Gastroenterol. 2012;5:359-370. [PMID: 22973419 DOI: 10.1177/1756283X12450245] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
218 Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management. J Am Acad Dermatol. 2012;67:1349-1361. [PMID: 22727462 DOI: 10.1016/j.jaad.2012.04.036] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
219 Revill P, Locarnini S. Antiviral strategies to eliminate hepatitis B virus covalently closed circular DNA (cccDNA). Current Opinion in Pharmacology 2016;30:144-50. [DOI: 10.1016/j.coph.2016.08.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
220 Huang YH, Lin HC, Lee SD. Reply to S. Kusumoto et al. J Clin Oncol 2013;31:4481. [PMID: 24220562 DOI: 10.1200/JCO.2013.53.4255] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
221 Svicher V, Cento V, Bernassola M, Neumann-fraune M, Hemert FV, Chen M, Salpini R, Liu C, Longo R, Visca M, Romano S, Micheli V, Bertoli A, Gori C, Ceccherini-silberstein F, Sarrecchia C, Andreoni M, Angelico M, Ursitti A, Spanò A, Zhang JM, Verheyen J, Cappiello G, Perno CF. Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. Antiviral Research 2012;93:86-93. [DOI: 10.1016/j.antiviral.2011.10.022] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 4.9] [Reference Citation Analysis]
222 Mizuno S, Yamagishi Y, Ebinuma H, Nakamoto N, Katahira M, Sasaki A, Sakamoto M, Suzuki H, Kanai T, Hibi T. Progressive liver failure induced by everolimus for renal cell carcinoma in a 58-year-old male hepatitis B virus carrier. Clin J Gastroenterol. 2013;6:188-192. [PMID: 23606919 DOI: 10.1007/s12328-013-0371-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
223 Kuo MT, Tseng PL, Chou YP, Chang KC, Tsai MC, Kuo YH, Hu TH, Hung CH, Wang JH, Lu SN, Chen CH. Role of hepatitis B surface antigen in hepatitis B virus relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapy. J Gastroenterol Hepatol 2018;33:1766-72. [PMID: 29514418 DOI: 10.1111/jgh.14142] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
224 Wu HL, Kao JH, Chen TC, Wu WH, Liu CH, Su TH, Yang HC, Chen DS, Chen PJ, Liu CJ. Serum cytokine/chemokine profiles in acute exacerbation of chronic hepatitis B: clinical and mechanistic implications. J Gastroenterol Hepatol 2014;29:1629-36. [PMID: 24730549 DOI: 10.1111/jgh.12606] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
225 Yuan L, Zeng BM, Liu LL, Ren Y, Yang YQ, Chu J, Li Y, Yang FW, He YH, Lin SD. Risk factors for progression to acute-on-chronic liver failure during severe acute exacerbation of chronic hepatitis B virus infection. World J Gastroenterol 2019;25:2327-37. [PMID: 31148904 DOI: 10.3748/wjg.v25.i19.2327] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
226 Mikulska M, Nicolini L, Signori A, Rivoli G, Del Bono V, Raiola A, Di Grazia C, Dominietto A, Varaldo R, Ghiso A, Bacigalupo A, Viscoli C. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome. Clinical Microbiology and Infection 2014;20:O694-701. [DOI: 10.1111/1469-0691.12611] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 7.4] [Reference Citation Analysis]
227 Sinha S, Kumar M. Pregnancy and chronic hepatitis B virus infection. Hepatol Res. 2010;40:31-48. [PMID: 20156298 DOI: 10.1111/j.1872-034x.2009.00597.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
228 Revill PA, Tu T, Netter HJ, Yuen LKW, Locarnini SA, Littlejohn M. The evolution and clinical impact of hepatitis B virus genome diversity. Nat Rev Gastroenterol Hepatol 2020;17:618-34. [DOI: 10.1038/s41575-020-0296-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 20.0] [Reference Citation Analysis]
229 Inoue J, Nakamura T, Masamune A. Roles of Hepatitis B Virus Mutations in the Viral Reactivation after Immunosuppression Therapies. Viruses 2019;11:E457. [PMID: 31109119 DOI: 10.3390/v11050457] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
230 Aggeletopoulou I, Konstantakis C, Manolakopoulos S, Triantos C. Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C. World J Gastroenterol 2017;23:4317-23. [PMID: 28706414 DOI: 10.3748/wjg.v23.i24.4317] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
231 Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol. 2011;8:275-284. [PMID: 21423260 DOI: 10.1038/nrgastro.2011.33] [Cited by in Crossref: 171] [Cited by in F6Publishing: 160] [Article Influence: 17.1] [Reference Citation Analysis]
232 Salpini R, Colagrossi L, Bellocchi MC, Surdo M, Becker C, Alteri C, Aragri M, Ricciardi A, Armenia D, Pollicita M, Di Santo F, Carioti L, Louzoun Y, Mastroianni CM, Lichtner M, Paoloni M, Esposito M, D'Amore C, Marrone A, Marignani M, Sarrecchia C, Sarmati L, Andreoni M, Angelico M, Verheyen J, Perno CF, Svicher V. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. Hepatology. 2015;61:823-833. [PMID: 25418031 DOI: 10.1002/hep.27604] [Cited by in Crossref: 80] [Cited by in F6Publishing: 76] [Article Influence: 13.3] [Reference Citation Analysis]
233 Aslam A, Susheela A, Iriana S, Chan SS, Lau D. Acute hepatitis E superinfection leading to chronic hepatitis B reactivation. BMJ Case Rep 2018;2018:bcr-2017-223616. [PMID: 29891510 DOI: 10.1136/bcr-2017-223616] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
234 Ekpanyapong S, Reddy KR. Hepatitis B Virus Reactivation: What Is the Issue, and How Should It Be Managed? Clin Liver Dis. 2020;24:317-333. [PMID: 32620274 DOI: 10.1016/j.cld.2020.04.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
235 Chen M, Chen M, Tsai C, Chou C, Lin H, Huang D, Huang Y. Incidence and antiviral response of hepatitis C virus reactivation in lupus patients undergoing immunosuppressive therapy. Lupus 2015;24:1029-36. [DOI: 10.1177/0961203315571465] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
236 Anastasiou OE, Almpani F, Herrmann A, Gerken G, Ditschkowski M, Ciesek S. HBV reactivation in allogeneic stem cell transplant recipients: Risk factors, outcome, and role of hepatitis B virus mutations. Hepatol Commun 2017;1:1014-23. [PMID: 29404439 DOI: 10.1002/hep4.1118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
237 Buzo BF, Ramos JF, Marques Rossetti RA, Salles N, Mendrone-Júnior A, Rocha V, de Seixas Santos Nastri AC. Hepatitis B virus among hematopoietic stem cell transplant recipients: Antiviral impact in seroconversion, engraftment, and mortality in a Latin American center. Transpl Infect Dis 2020;22:e13243. [PMID: 31901206 DOI: 10.1111/tid.13243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
238 Bonifati C, Lora V, Graceffa D, Nosotti L. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol. 2016;22:6444-6455. [PMID: 27605880 DOI: 10.3748/wjg.v22.i28.6444] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
239 Manka P, Verheyen J, Gerken G, Canbay A. Liver Failure due to Acute Viral Hepatitis (A-E). Visc Med 2016;32:80-5. [PMID: 27413724 DOI: 10.1159/000444915] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
240 Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev. 2012;25:142-163. [PMID: 22232374 DOI: 10.1128/cmr.00018-11] [Cited by in Crossref: 91] [Cited by in F6Publishing: 52] [Article Influence: 10.1] [Reference Citation Analysis]
241 Fujiwara K, Yasui S, Okitsu K, Yonemitsu Y, Oda S, Yokosuka O. The requirement for a sufficient period of corticosteroid treatment in combination with nucleoside analogue for severe acute exacerbation of chronic hepatitis B. J Gastroenterol. 2010;45:1255-1262. [PMID: 20614156 DOI: 10.1007/s00535-010-0280-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
242 Moses J, Alkhouri N, Shannon A, Raig K, Lopez R, Danziger-Isakov L, Feldstein AE, Zein NN, Wyllie R, Carter-Kent C. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab. Am J Gastroenterol. 2012;107:133-138. [PMID: 21876562 DOI: 10.1038/ajg.2011.295] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 5.0] [Reference Citation Analysis]
243 Sohn W, Paik YH, Cho JY, Ahn JM, Choi GS, Kim JM, Kwon CH, Joh JW, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Influence of hepatitis B virus reactivation on the recurrence of HBV-related hepatocellular carcinoma after curative resection in patients with low viral load. J Viral Hepat 2015;22:539-50. [PMID: 25377516 DOI: 10.1111/jvh.12356] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
244 Ling WH, Soe PP, Pang AS, Lee SC. Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours. Br J Cancer. 2013;108:1931-1935. [PMID: 23652302 DOI: 10.1038/bjc.2013.225] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
245 Seeger C, Litwin S, Mason WS. Hepatitis B Virus: Persistence and Clearance. In: Liaw Y, Zoulim F, editors. Hepatitis B Virus in Human Diseases. Cham: Springer International Publishing; 2016. pp. 123-45. [DOI: 10.1007/978-3-319-22330-8_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
246 Bestas R, Yalcin K. Clinical and Virological Features of Acute Hepatic Exacerbations in Patients With Chronic Hepatitis B Virus Infection. Cureus 2021;13:e15937. [PMID: 34194888 DOI: 10.7759/cureus.15937] [Reference Citation Analysis]
247 Mori S. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Modern Rheumatology 2014;21:621-7. [DOI: 10.3109/s10165-011-0458-z] [Cited by in Crossref: 43] [Cited by in F6Publishing: 23] [Article Influence: 6.1] [Reference Citation Analysis]
248 Yu WH, Cosgrove C, Berger CT, Cheney PC, Krykbaeva M, Kim AY, Lewis-Ximenez L, Lauer GM, Alter G. ADCC-Mediated CD56DIM NK Cell Responses Are Associated with Early HBsAg Clearance in Acute HBV Infection. Pathog Immun 2018;3:2-18. [PMID: 29541698 DOI: 10.20411/pai.v3i1.228] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
249 Rubio J, Franco F, Sánchez A, Cantos B, Méndez M, Calvo V, Maximiano C, Perez D, Millán I, Sánchez-Beato M. Does the presence of hepatitis virus B and C influence the evolution of diffuse large B-cell lymphoma? Leuk Lymphoma. 2015;56:1686-1690. [PMID: 25219591 DOI: 10.3109/10428194.2014.963576] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
250 Ridruejo E. Antiviral treatment for chronic hepatitis B in renal transplant patients. World J Hepatol. 2015;7:189-203. [PMID: 25729474 DOI: 10.4254/wjh.v7.i2.189] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
251 Patel A, Yapali S, Lok AS. Admissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014. Hepatol Int 2016;10:139-46. [PMID: 26272106 DOI: 10.1007/s12072-015-9659-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
252 Bar-Yishay I, Shaul Y, Shlomai A. Hepatocyte metabolic signalling pathways and regulation of hepatitis B virus expression. Liver Int. 2011;31:282-290. [PMID: 21281428 DOI: 10.1111/j.1478-3231.2010.02423.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 6.0] [Reference Citation Analysis]
253 Sedhom D, D'Souza M, John E, Rustgi V. Viral Hepatitis and Acute Liver Failure: Still a Problem. Clin Liver Dis. 2018;22:289-300. [PMID: 29605067 DOI: 10.1016/j.cld.2018.01.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
254 Cao Z, Liu Y, Ma L, Lu J, Jin Y, Ren S, He Z, Shen C, Chen X. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha. Hepatology. 2017;66:1058-1066. [PMID: 28407271 DOI: 10.1002/hep.29213] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 7.5] [Reference Citation Analysis]
255 Dobrica MO, Lazar C, Branza-Nichita N. N-Glycosylation and N-Glycan Processing in HBV Biology and Pathogenesis. Cells 2020;9:E1404. [PMID: 32512942 DOI: 10.3390/cells9061404] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
256 Marignani M, Marzano A, Begini P, Vitolo U, Luminari S, Levis A, Deli I, Gigante E, De Santis E, delle Fave G, Monarca B, Cox MC. Perception of hepatitis B virus infection reactivation-related issues among specialists managing hematologic malignancies: result of an Italian survey. Leuk Lymphoma 2014;55:2564-71. [PMID: 24471911 DOI: 10.3109/10428194.2013.879712] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
257 Marignani M, Gigante E, Begini P, Marzano A, di Fonzo M, Deli I, Gallina S, Cox MC, Delle Fave G. Patients with hematological malignancies and serological signs of prior resolved hepatitis B. World J Gastrointest Oncol 2012;4:37-45. [PMID: 22468182 DOI: 10.4251/wjgo.v4.i3.37] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
258 Sarin SK, Kedarisetty CK, Abbas Z, Amarapurkar D, Bihari C, Chan AC, Chawla YK, Dokmeci AK, Garg H, Ghazinyan H, Hamid S, Kim DJ, Komolmit P, Lata S, Lee GH, Lesmana LA, Mahtab M, Maiwall R, Moreau R, Ning Q, Pamecha V, Payawal DA, Rastogi A, Rahman S, Rela M, Saraya A, Samuel D, Saraswat V, Shah S, Shiha G, Sharma BC, Sharma MK, Sharma K, Butt AS, Tan SS, Vashishtha C, Wani ZA, Yuen MF, Yokosuka O;  APASL ACLF Working Party. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatol Int. 2014;8:453-471. [PMID: 26202751 DOI: 10.1007/s12072-014-9580-2] [Cited by in Crossref: 354] [Cited by in F6Publishing: 281] [Article Influence: 50.6] [Reference Citation Analysis]
259 Lok AS, Ward JW, Perrillo RP, McMahon BJ, Liang TJ. Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable. Ann Intern Med. 2012;156:743-745. [PMID: 22586011 DOI: 10.7326/0003-4819-156-10-201205150-00013] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
260 Jang JW. Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy. World J Gastroenterol. 2014;20:7675-7685. [PMID: 24976705 DOI: 10.3748/wjg.v20.i24.7675] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
261 Eun Y, Kim IY, Jeong H, Kim H, Lee J, Choi MS, Koh E, Cha HS. Disease Characteristics and Change in Arthritis Activity according to Treatment in Hepatitis B Surface Antigen-positive Rheumatoid Arthritis Patients: a Retrospective Chart Review Study. J Korean Med Sci 2018;33:e168. [PMID: 29853822 DOI: 10.3346/jkms.2018.33.e168] [Reference Citation Analysis]
262 Watanabe M, Shibuya A, Takada J, Tanaka Y, Okuwaki Y, Minamino T, Hidaka H, Nakazawa T, Koizumi W. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients. Eur J Intern Med. 2010;21:333-337. [PMID: 20603047 DOI: 10.1016/j.ejim.2010.04.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
263 Li MH, Yi W, Zhang L, Lu Y, Lu HH, Shen G, Wu SL, Hao HX, Gao YJ, Chang M, Liu RY, Hu LP, Cao WH, Chen QQ, Li JN, Wan G, Xie Y. Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy. J Viral Hepat 2019;26 Suppl 1:32-41. [PMID: 31380582 DOI: 10.1111/jvh.13151] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
264 Han GR, Xu CL, Zhao W, Yang YF. Management of chronic hepatitis B in pregnancy. World J Gastroenterol. 2012;18:4517-4521. [PMID: 22969224 DOI: 10.3748/wjg.v18.i33.4517] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
265 Hu L, Chen L, Li L, Sun H, Yang G, Chang Y, Tu Q, Wu M, Wang H. Hepatitis B virus X protein enhances cisplatin-induced hepatotoxicity via a mechanism involving degradation of Mcl-1. J Virol 2011;85:3214-28. [PMID: 21228225 DOI: 10.1128/JVI.01841-10] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
266 Koskinas JS, Deutsch M, Adamidi S, Skondra M, Tampaki M, Alexopoulou A, Manolakopoulos S, Pectasides D. The role of tenofovir in preventing and treating hepatitis B virus (HBV) reactivation in immunosuppressed patients. A real life experience from a tertiary center. Eur J Intern Med. 2014;25:768-771. [PMID: 25037900 DOI: 10.1016/j.ejim.2014.06.028] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
267 Canzoni M, Marignani M, Sorgi ML, Begini P, Biondo MI, Caporuscio S, Colonna V, Casa FD, Conigliaro P, Marrese C, Celletti E, Modesto I, Peragallo MS, Laganà B, Picchianti-Diamanti A, Rosa RD, Ferlito C, Salemi S, D'Amelio R, Stroffolini T. Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy. Microorganisms 2020;8:E1792. [PMID: 33207663 DOI: 10.3390/microorganisms8111792] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
268 Yang JD, Girotra M, Restrepo A, Waheed S, Barlogie B, Duarte-rojo A. Hepatitis B reactivation in patients with multiple myeloma and isolated positive hepatitis B core antibody: a call for greater cognizance. Annals of Hepatology 2014;13:461-5. [DOI: 10.1016/s1665-2681(19)30855-5] [Cited by in Crossref: 9] [Article Influence: 1.3] [Reference Citation Analysis]
269 Watanabe M, Shibuya A, Tsunoda Y, Danbara M, Ishii R, Ohsaka M, Takada J, Tanaka Y, Okuwaki Y, Minamino T, Hidaka H, Nakazawa T, Horie R, Higashihara M, Koizumi W. Re-appearance of hepatitis B virus following therapy with rituximab for lymphoma is not rare in Japanese patients with past hepatitis B virus infection: Re-appearance of HBV after chemotherapy. Liver International 2011;31:340-7. [DOI: 10.1111/j.1478-3231.2010.02417.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
270 Cabibbo G, Palmeri L, Palmeri S, Craxì A. Should cirrhosis change our attitude towards treating non-hepatic cancer? Liver Int. 2012;32:21-27. [PMID: 22098398 DOI: 10.1111/j.1478-3231.2011.02629.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
271 Dalia S, Suleiman Y, Croy DW, Sokol L. Association of Lymphomagenesis and the Reactivation of Hepatitis B Virus in Non-Hodgkin Lymphoma. Cancer Control 2015;22:360-5. [PMID: 26351893 DOI: 10.1177/107327481502200315] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
272 Kim HG, Kim EY, Yu YJ, Kim GH, Jeong JW, Byeon JH, Chung BH, Yang CW. Comparison of clinical outcomes in hepatitis B virus-positive kidney transplant recipients with or without pretransplantation antiviral therapy. Transplant Proc. 2013;45:1374-1378. [PMID: 23726576 DOI: 10.1016/j.transproceed.2013.01.088] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
273 Huang YW, Chung RT. Management of hepatitis B reactivation in patients receiving cancer chemotherapy. Therap Adv Gastroenterol. 2012;5:359-370. [PMID: 22973419 DOI: 10.1177/1756283x1245024510.1177_1756283x12450245] [Reference Citation Analysis]
274 Londoño M, Carrión JA, Forns X. Letter: hepatitis B reactivation in patients with chronic hepatitis C during direct-acting antiviral therapy-authors' reply. Aliment Pharmacol Ther 2017;45:1559-60. [DOI: 10.1111/apt.14104] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
275 Chen FW, Coyle L, Jones BE, Pattullo V. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease. Liver Int 2013;33:1203-10. [DOI: 10.1111/liv.12154] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
276 McMahon BJ. Chronic hepatitis B virus infection. Med Clin North Am. 2014;98:39-54. [PMID: 24266913 DOI: 10.1016/j.mcna.2013.08.004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 6.8] [Reference Citation Analysis]
277 Stasi C, Tiengo G, Sadalla S, Zignego AL. Treatment or Prophylaxis against Hepatitis B Virus Infection in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: An Update. J Clin Med 2021;10:2564. [PMID: 34200522 DOI: 10.3390/jcm10122564] [Reference Citation Analysis]
278 Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology. 2015;61:703-711. [PMID: 25412906 DOI: 10.1002/hep.27609] [Cited by in Crossref: 134] [Cited by in F6Publishing: 110] [Article Influence: 22.3] [Reference Citation Analysis]
279 Seetharam A, Perrillo R, Gish R. Immunosuppression in Patients with Chronic Hepatitis B. Curr Hepatol Rep. 2014;13:235-244. [PMID: 25101233 DOI: 10.1007/s11901-014-0238-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 5.1] [Reference Citation Analysis]
280 Pol S. Management of HBV in immunocompromised patients. Liver Int. 2013;33 Suppl 1:182-187. [PMID: 23286863 DOI: 10.1111/liv.12055] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
281 Koutsianas C, Thomas K, Vassilopoulos D. Hepatitis B Reactivation in Rheumatic Diseases: Screening and Prevention. Rheum Dis Clin North Am 2017;43:133-49. [PMID: 27890170 DOI: 10.1016/j.rdc.2016.09.012] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
282 Martín Hidalgo-Barquero MV, Ruiz-Calero Cendrero RM, Cancho Castellano B, Cid Parra MC, Galán González J. Chemotherapy and occult reactivation of HBV in hemodialysis patients. Nefrologia (Engl Ed) 2020;40:565-6. [PMID: 31627973 DOI: 10.1016/j.nefro.2019.06.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
283 Karvellas CJ, Cardoso FS, Gottfried M, Reddy KR, Hanje AJ, Ganger D, Lee WM;  US Acute Liver Failure Study Group. HBV-Associated Acute Liver Failure After Immunosuppression and Risk of Death. Clin Gastroenterol Hepatol. 2017;15:113-122. [PMID: 27311622 DOI: 10.1016/j.cgh.2016.06.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
284 Morillas RM, López Sisamón D. Reactivación de la hepatitis B asociada a agentes inmunodepresores y a quimioterapia. Historia natural, factores de riesgo y recomendaciones para prevenirla. Medicina Clínica 2019;152:107-14. [DOI: 10.1016/j.medcli.2018.08.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
285 Manzano-Alonso ML, Castellano-Tortajada G. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J Gastroenterol. 2011;17:1531-1537. [PMID: 21472116 DOI: 10.3748/wjg.v17.i12.1531] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 53] [Article Influence: 5.5] [Reference Citation Analysis]
286 Salpini R, Battisti A, Colagrossi L, Di Carlo D, Fabeni L, Piermatteo L, Cerva C, Lichtner M, Mastroianni C, Marignani M, Maylin S, Delaugerre C, Morisco F, Coppola N, Marrone A, Angelico M, Sarmati L, Andreoni M, Perno CF, Ceccherini-Silberstein F, Svicher V. A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection. J Viral Hepat 2019;26:846-55. [PMID: 30974483 DOI: 10.1111/jvh.13101] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
287 Mouler Rechtman M, Burdelova EO, Bar-Yishay I, Ben-Yehoyada M, Fishman S, Halpern Z, Shlomai A. The metabolic regulator PGC-1α links anti-cancer cytotoxic chemotherapy to reactivation of hepatitis B virus. J Viral Hepat 2013;20:34-41. [PMID: 23231082 DOI: 10.1111/j.1365-2893.2012.01622.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
288 Selmi C, Ceribelli A, Naguwa SM, Cantarini L, Shoenfeld Y. Safety issues and concerns of new immunomodulators in rheumatology. Expert Opin Drug Saf. 2015;14:389-399. [PMID: 25518908 DOI: 10.1517/14740338.2015.993605] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
289 Chen LF, Mo YQ, Jing J, Ma JD, Zheng DH, Dai L. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation. Int J Rheum Dis. 2017;20:859-869. [PMID: 28160426 DOI: 10.1111/1756-185x.13010] [Cited by in Crossref: 47] [Cited by in F6Publishing: 24] [Article Influence: 11.8] [Reference Citation Analysis]
290 Kim J, Chung SJ, Sinn DH, Lee KW, Park JB, Huh W, Lee JE, Jang HR, Kang W, Gwak G, Paik Y, Choi MS, Lee JH, Koh KC, Paik SW. Hepatitis B reactivation after kidney transplantation in hepatitis B surface antigen‐negative, core antibody‐positive recipients. J Viral Hepat 2020;27:739-46. [DOI: 10.1111/jvh.13279] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
291 Salpini R, Pietrobattista A, Piermatteo L, Basso MS, Bellocchi MC, Liccardo D, Carioti L, Francalanci P, Aragri M, Alkhatib M, Scutari R, Candusso M, Ciotti M, Svicher V. Establishment of a Seronegative Occult Infection With an Active Hepatitis B Virus Reservoir Enriched of Vaccine Escape Mutations in a Vaccinated Infant After Liver Transplantation. J Infect Dis 2019;220:1935-9. [PMID: 31412121 DOI: 10.1093/infdis/jiz411] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
292 Kwan KW, Lim TR, Kumar R, Krishnamoorthy TL. Understanding the hepatitis B core positive liver donor. Singapore Med J. 2018;. [PMID: 30182132 DOI: 10.11622/smedj.2018104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
293 Sarin SK, Choudhury A, Sharma MK, Maiwall R, Al Mahtab M, Rahman S, Saigal S, Saraf N, Soin AS, Devarbhavi H, Kim DJ, Dhiman RK, Duseja A, Taneja S, Eapen CE, Goel A, Ning Q, Chen T, Ma K, Duan Z, Yu C, Treeprasertsuk S, Hamid SS, Butt AS, Jafri W, Shukla A, Saraswat V, Tan SS, Sood A, Midha V, Goyal O, Ghazinyan H, Arora A, Hu J, Sahu M, Rao PN, Lee GH, Lim SG, Lesmana LA, Lesmana CR, Shah S, Prasad VGM, Payawal DA, Abbas Z, Dokmeci AK, Sollano JD, Carpio G, Shresta A, Lau GK, Fazal Karim M, Shiha G, Gani R, Kalista KF, Yuen MF, Alam S, Khanna R, Sood V, Lal BB, Pamecha V, Jindal A, Rajan V, Arora V, Yokosuka O, Niriella MA, Li H, Qi X, Tanaka A, Mochida S, Chaudhuri DR, Gane E, Win KM, Chen WT, Rela M, Kapoor D, Rastogi A, Kale P, Sharma CB, Bajpai M, Singh V, Premkumar M, Maharashi S, Olithselvan A, Philips CA, Srivastava A, Yachha SK, Wani ZA, Thapa BR, Saraya A, Shalimar, Kumar A, Wadhawan M, Gupta S, Madan K, Sakhuja P, Vij V, Sharma BC, Garg H, Garg V, Kalal C, Anand L, Vyas T, Mathur RP, Kumar G, Jain P, Pasupuleti SSR, Chawla YK, Chowdhury A, Song DS, Yang JM, Yoon EL;  APASL ACLF Research Consortium (AARC) for APASL ACLF working Party. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019;13:353-390. [PMID: 31172417 DOI: 10.1007/s12072-019-09946-3] [Cited by in Crossref: 134] [Cited by in F6Publishing: 91] [Article Influence: 67.0] [Reference Citation Analysis]
294 Londoño MC, Lens S, Mariño Z, Bonacci M, Ariza X, Broquetas T, Pla A, Bartres C, Adriani MV, Rodríguez-Tajes S, Costa J, Carrión JA, Pérez-Del-Pulgar S, Forns X. Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti-viral therapy with an interferon-free regimen. Aliment Pharmacol Ther 2017;45:1156-61. [PMID: 28206681 DOI: 10.1111/apt.13985] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 9.5] [Reference Citation Analysis]
295 Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev. 2012;25:142-163. [PMID: 22232374 DOI: 10.1128/cmr.00018-1125/1/142] [Reference Citation Analysis]
296 Moleti M, Giuffrida G, Sturniolo G, Squadrito G, Campennì A, Morelli S, Puxeddu E, Sisti E, Trimarchi F, Vermiglio F, Marinò M. Acute liver damage following intravenous glucocorticoid treatment for Graves’ ophthalmopathy. Endocrine 2016;54:259-68. [DOI: 10.1007/s12020-016-0928-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
297 Lunel-Fabiani F, Masson C, Ducancelle A. Systemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation. Joint Bone Spine. 2014;81:478-484. [PMID: 24561021 DOI: 10.1016/j.jbspin.2014.01.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
298 Vassilopoulos D, Manolakopoulos S. Rheumatic manifestations of hepatitis. Current Opinion in Rheumatology 2010;22:91-6. [DOI: 10.1097/bor.0b013e328333ba5d] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
299 Kalia H, Fabrizi F, Martin P. Hepatitis B virus and renal transplantation. Transplant Rev (Orlando) 2011;25:102-9. [PMID: 21530218 DOI: 10.1016/j.trre.2011.02.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
300 Altinbaş A, Yüksel L, Pamukcu M, Ekiz F, Başar Ö, Yüksel O. Spontaneous HBsAg seroconversion after severe flare of chronic hepatitis B infection. Annals of Hepatology 2010;9:194-7. [DOI: 10.1016/s1665-2681(19)31662-x] [Cited by in Crossref: 5] [Article Influence: 0.5] [Reference Citation Analysis]
301 Law MF, Ho R, Cheung CK, Tam LH, Ma K, So KC, Ip B, So J, Lai J, Ng J, Tam TH. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. World J Gastroenterol. 2016;22:6484-6500. [PMID: 27605883 DOI: 10.3748/wjg.v22.i28.6484] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 34] [Article Influence: 10.5] [Reference Citation Analysis]
302 Jun CH, Kim BS, Oak CY, Lee DH, Cho E, Cho SB, Choi SK, Park CH, Joo YE, Lee JJ, Kim HJ. HBV reactivation risk factors in patients with chronic HBV infection with low replicative state and resolved HBV infection undergoing hematopoietic stem cell transplantation in Korea. Hepatol Int 2017;11:87-95. [PMID: 27351765 DOI: 10.1007/s12072-016-9747-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
303 Mori S, Fujiyama S. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. World J Gastroenterol 2015;21:10274-89. [PMID: 26420955 DOI: 10.3748/wjg.v21.i36.10274] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 46] [Article Influence: 11.2] [Reference Citation Analysis]
304 Claridge LC, Dobson C, Kanji H, Neil D, Timms JM, Holt AP. Acute liver failure secondary to opportunistic viral infection in adult solid organ transplant recipients. QJM 2012;105:879-82. [PMID: 21771853 DOI: 10.1093/qjmed/hcr117] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
305 Xu Z, Pan X, Wei K, Ding H, Wei M, Yang H, Liu Q. Serum Golgi protein 73 levels and liver pathological grading in cases of chronic hepatitis B. Mol Med Rep. 2015;11:2644-2652. [PMID: 25524053 DOI: 10.3892/mmr.2014.3114] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
306 Parker R, Oo YH, Adams DH. Management of patients with difficult autoimmune hepatitis. Therap Adv Gastroenterol. 2012;5:421-437. [PMID: 23152735 DOI: 10.1177/1756283X12450251] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
307 Guo L, Wang D, Ouyang X, Tang N, Chen X, Zhang Y, Zhu H, Li X. Recent Advances in HBV Reactivation Research. Biomed Res Int. 2018;2018:2931402. [PMID: 30687740 DOI: 10.1155/2018/2931402] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
308 Keith P, Wetter D, Wilson J, Lehman J. Evidence-based guidelines for laboratory screening for infectious diseases before initiation of systemic immunosuppressive agents in patients with autoimmune bullous dermatoses. Br J Dermatol 2014;171:1307-17. [DOI: 10.1111/bjd.13355] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
309 Lenci I, Milana M, Grassi G, Manzia TM, Gazia C, Tisone G, Angelico R, Baiocchi L. Hepatitis B virus recurrence after liver transplantation: An old tale or a clear and present danger? World J Gastroenterol 2020;26:2166-76. [PMID: 32476783 DOI: 10.3748/wjg.v26.i18.2166] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
310 Vassilopoulos D, Calabrese LH. Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev Rheumatol 2012;8:348-57. [DOI: 10.1038/nrrheum.2012.63] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
311 Papastergiou V, Burroughs AK, Tsochatzis EA. Prognosis and treatment of patients with acute alcoholic hepatitis. Expert Rev Gastroenterol Hepatol. 2014;8:471-486. [PMID: 24716632 DOI: 10.1586/17474124.2014.903800] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
312 Fylaktou A, Daoudaki M, Dimou V, Sianou E, Papaventsis D, Mavrovouniotis I, Fouzas I, Papanikolaou V. Hepatitis B Reactivation in a Renal Transplant Patient Due to a Surface Antigen Mutant Strain: A Case Report. Transplantation Proceedings 2012;44:2773-5. [DOI: 10.1016/j.transproceed.2012.09.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
313 Piaserico S, Messina F, Russo FP. Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations. Am J Clin Dermatol 2019;20:829-45. [PMID: 31222626 DOI: 10.1007/s40257-019-00457-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
314 Salek J, Byrne J, Box T, Longo N, Sussman N. Recurrent liver failure in a 25-year-old female. Liver Transpl 2010;16:1049-53. [DOI: 10.1002/lt.22118] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]